- https://doi.org/10.1007/s11654-025-00685-6
Organerhaltende Therapie des muskelinvasiven Harnblasenkarzinoms
Abstract
Translate Article 
Take Notes
Translate Article Take Notes Organerhaltende Therapie des muskelinvasiven Harnblasenkarzinoms
ReferencesShowing 10 of 23 papersRadiotherapy with or without Chemotherapy in Muscle-Invasive Bladder Cancer Long-Term Experience of Chemoradiotherapy Combined with Deep Regional Hyperthermia for Organ Preservation in High-Risk Bladder Cancer (Ta, Tis, T1, T2). A comparative analysis of radical cystectomy with perioperative chemotherapy, chemoradiation therapy, or systemic therapy in patients with clinically advanced node-positive bladder cancer (cN2/N3). Radical cystectomy versus trimodality therapy for muscle-invasive bladder cancer: a multi-institutional propensity score matched and weighted analysis. Similar Treatment Outcomes for Radical Cystectomy and Radical Radiotherapy in Invasive Bladder Cancer Treated at a United Kingdom Specialist Treatment Center Chemoradiotherapy in Muscle-invasive Bladder Cancer: 10-yr Follow-up of the Phase 3 Randomised Controlled BC2001 Trial Contemporary use trends and survival outcomes in patients undergoing radical cystectomy or bladder-preservation therapy for muscle-invasive bladder cancer. LIFE AND DEATH OF SPARE (SELECTIVE BLADDER PRESERVATION AGAINST RADICAL EXCISION): REFLECTIONS ON WHY THE SPARE TRIAL CLOSED Perioperative Durvalumab with Neoadjuvant Chemotherapy in Operable Bladder Cancer The Emerging Evidence Supporting Integration of Deep Regional Hyperthermia With Chemoradiation in Bladder Cancer
855 - 10.1056/nejmoa1106106
- Apr 19, 2012
- New England Journal of Medicine
- 33
- 10.1634/theoncologist.2018-0280
- Jul 10, 2019
- The Oncologist
- 10.3389/fonc.2023.1157880
- Jan 11, 2024
- Frontiers in oncology
- 137
- 10.1016/s1470-2045(23)00170-5
- Jun 1, 2023
- The Lancet Oncology
- 131
- 10.1016/j.ijrobp.2007.06.030
- Sep 27, 2007
- International Journal of Radiation Oncology*Biology*Physics
- 77
- 10.1016/j.eururo.2022.04.017
- May 14, 2022
- European Urology
- 87
- 10.1002/cncr.30900
- Jul 25, 2017
- Cancer
- 120
- 10.1111/j.1464-410x.2010.09537.x
- Aug 12, 2010
- BJU International
- 88
- 10.1056/nejmoa2408154
- Sep 15, 2024
- New England Journal of Medicine
- 3
- 10.1016/j.semradonc.2022.10.011
- Dec 13, 2022
- Seminars in Radiation Oncology
More from: best practice onkologieonko-aktuell Sequenztherapie des metastasierten kolorektalen Karzinoms Wichtige Studien vom ASCO 2025 Einsatz von funktioneller Bildgebung zur Therapieplanung Editorial Organerhaltende Therapie des muskelinvasiven Harnblasenkarzinoms Der erste Schritt zur kontextbewussten Medizin ist das Aufdecken der „blinden Flecken“ onko-aktuell Für Strategie bleibt da keine Zeit Wichtige Studien vom ASCO 2025
- Research Article
- 10.1007/s11654-025-00696-3
- Oct 22, 2025
- best practice onkologie
- Research Article
- 10.1007/s11654-025-00697-2
- Oct 21, 2025
- best practice onkologie
- Research Article
- 10.1007/s11654-025-00694-5
- Oct 6, 2025
- best practice onkologie
- Research Article
- 10.1007/s11654-025-00689-2
- Oct 1, 2025
- best practice onkologie
- Research Article
- 10.1007/s11654-025-00692-7
- Oct 1, 2025
- best practice onkologie
- Research Article
- 10.1007/s11654-025-00685-6
- Sep 22, 2025
- best practice onkologie
- Research Article
- 10.1007/s11654-025-00691-8
- Sep 19, 2025
- best practice onkologie
- Research Article
- 10.1007/s11654-025-00693-6
- Sep 19, 2025
- best practice onkologie
- Research Article
- 10.1007/s11654-025-00687-4
- Sep 12, 2025
- best practice onkologie
- Research Article
- 10.1007/s11654-025-00684-7
- Sep 9, 2025
- best practice onkologie
- Ask R Discovery
- Chat PDF
AI summaries and top papers from 250M+ research sources.
What is the difference between bacteria and viruses?
What is the function of the immune system?Can diabetes be passed down from one generation to the next?